Lucentis, Genentech

Study explores ranibizumab as treatment for ROPIntravitreal ranibizumab (Lucentis, Genentech) appears to be effective for treatment of severe retinopathy of prematurity (ROP) and associated with less persistent suppression of systemic VEGF compared with bevacizumab (Avastin, Genentech), according to research reported by Shunji Kusaka, MD.
When diabetes goes from bad to worseA 30-year-old female with a 16-year history of insulin-dependent diabetes and no other ocular or systemic conditions developed proliferative retinopathy in March 2015. She had not been closely followed for the previous five years.
Using OCT with your diabetes patientsOCT is one of the best way to assess patients for the presence of diabetic macular edema (DME)
What’s new for diabetes management and prevention
What’s new for diabetes management and preventionFrom new ways of predicting who will and won’t develop diabetes, to new diabetes meds, to new evidence regarding which anti-vascular endothelial growth factor (VEGF) might be better for your specific patient, the last year has given us better tools for helping our patients with diabetes.
Novartis deterred UK physicians from prescribing Avastin, report saysNovartis attempted to block studies in the United Kingdom comparing ranibizumab (Lucentis) and bevacizumab (Avastin) for the treatment of wet age-related macular degeneration (AMD), according to an article published in The BJM, an international peer-reviewed medical journal.
Ranibizumab effective for managing pigment epithelial detachmentsRanibizumab effectively managed pigment epithelial detachments in patients with wet age-related macular degeneration regardless of size at baseline.
Anti-VEGF treatment helps diabetic patientA 76-year-old white female presented for her periodic diabetic eye examination at UAB Eye Care in July 2014. She admitted to blurry vision in her left eye for approximately one week.
AMD treatment market to exceed $10 billion by 2023According to a report from GlobalData, the age-related macular degeneration treatment market in the U.S., UK, Germany, France, Spain, Italy, and Japan will double in value from $5.1 billion in 2013 to $10.1 billion in 2023.
Drugs for AMD and DME still in center courtMuch of the developments in pharmacologic therapy for retina disease revolved around age-related macular degeneration and diabetic macular edema in 2014.
FDA approves Eylea for all forms of macular edema after retinal vein occlusionThe U.S. Food and Drug Administration (FDA) recently approved Eylea (afilbercept, Regeneron) for all forms of macular edema after retinal vein occlusion, including branch retinal vein occlusion.